Ionis partner GSK wins US approval for Hibsago to treat chronic hepatitis B

• Ionis Pharmaceuticals partner GSK secured U.S. FDA approval for Hibsago, or bepirovirsen, with antiviral therapy for eligible adults with chronic hepatitis B.
• Reported Phase 3 results showed a six-month course improved functional cure outcomes versus placebo, allowing some patients to remain off treatment.
• Use is limited to adults without cirrhosis whose infection is suppressed following at least six months of antiviral therapy.
• Boxed warnings cover liver flares and potentially life-threatening platelet reductions.
• GSK licensed bepirovirsen in 2019; the agreement provides additional milestone payments and tiered royalties of 10-12% on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610202120BIZWIRE_USPR_____20261020_BW102530) on October 21, 2026, and is solely responsible for the information contained therein.